Details for New Drug Application (NDA): 022483
✉ Email this page to a colleague
The generic ingredient in ZYCLARA is imiquimod. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the imiquimod profile page.
Pharmacology for NDA: 022483
Mechanism of Action | Interferon Inducers |
Physiological Effect | Increased Cytokine Activity Increased Cytokine Production |
Suppliers and Packaging for NDA: 022483
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ZYCLARA | imiquimod | CREAM;TOPICAL | 022483 | NDA AUTHORIZED GENERIC | Teva Pharmaceuticals USA, Inc. | 0093-3133 | 0093-3133-31 | 1 BOTTLE, PUMP in 1 CARTON (0093-3133-31) / 7.5 g in 1 BOTTLE, PUMP |
ZYCLARA | imiquimod | CREAM;TOPICAL | 022483 | NDA AUTHORIZED GENERIC | Bryant Ranch Prepack | 63629-8818 | 63629-8818-1 | 1 BOTTLE, PUMP in 1 CARTON (63629-8818-1) / 7.5 g in 1 BOTTLE, PUMP |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CREAM;TOPICAL | Strength | 3.75% | ||||
Approval Date: | Mar 25, 2010 | TE: | AB | RLD: | Yes | ||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 11, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF ACTINIC KERATOSIS | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 18, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF GENITAL WARTS | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Aug 18, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | TREATMENT OF PERIANAL WARTS |
Complete Access Available with Subscription